Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha
- PMID: 2788651
Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha
Abstract
T3M4 human pancreatic carcinoma cells avidly bound and internalized 125I-labeled epidermal growth factor (EGF) but did not readily degrade the ligand. Pulse-chase experiments in which the cell-bound radioactivity was allowed to dissociate into the incubation medium in the presence of unlabeled EGF indicated that the majority of the released 125I-EGF consisted of intact EGF and a slightly processed species that readily bound to the cell. Omission of unlabeled EGF during the chase period markedly decreased the amount of radioactivity in the incubation medium, mainly as a result of the rebinding of EGF to the cells. In contrast, T3M4 cells readily degraded 125I-labeled transforming growth factor-alpha (TGF-alpha), and the released radiolabeled products did not rebind to the cells. Both ligands were released from T3M4 cells under acidic conditions, complete dissociation occurring at a pH of 4.5 for EGF, and a pH of 6.5 for TGF-alpha. A 431 human epidermoid carcinoma cells and ASPC-1 human pancreatic carcinoma cells also failed to extensively degrade 125I-EGF, whereas Rat-1 fibroblasts markedly degraded the growth factor. As in the case of T3M4 cells, ASPC-1 cells extensively degraded 125I-TGF-alpha. Degradation of either ligand was blocked by the lysosomotropic compound methylamine in all the tested cell lines. Immunoprecipitation of the EGF receptor with specific polyclonal antibodies and Western blot analysis revealed the anticipated 170-kDa protein in T3M4 cells. Both EGF and TGF-alpha enhanced EGF receptor degradation, but TGF-alpha was less effective than EGF. These findings indicate that in certain cell types EGF and TGF-alpha may be differentially processed.
Similar articles
-
Divergent effects of epidermal growth factor and transforming growth factors on a human endometrial carcinoma cell line.Cancer Res. 1987 Sep 15;47(18):4909-14. Cancer Res. 1987. PMID: 3497713
-
Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.Proc Natl Acad Sci U S A. 1987 Nov;84(21):7567-70. doi: 10.1073/pnas.84.21.7567. Proc Natl Acad Sci U S A. 1987. PMID: 3499610 Free PMC article.
-
Recycling of epidermal growth factor in a human pancreatic carcinoma cell line.Proc Natl Acad Sci U S A. 1985 Sep;82(18):6172-5. doi: 10.1073/pnas.82.18.6172. Proc Natl Acad Sci U S A. 1985. PMID: 2994064 Free PMC article.
-
Differential binding and biological activities of epidermal growth factor and transforming growth factor alpha in a human pancreatic cancer cell line.Cancer Res. 1991 Dec 1;51(23 Pt 1):6243-9. Cancer Res. 1991. PMID: 1933884
-
Potential role of the epidermal growth factor receptor in human pancreatic cancer.Int J Pancreatol. 1990 Aug-Nov;7(1-3):71-81. doi: 10.1007/BF02924222. Int J Pancreatol. 1990. PMID: 2081930 Review.
Cited by
-
Growth factors and pancreatic cancer.Int J Pancreatol. 1991 Summer;9:87-91. doi: 10.1007/BF02925583. Int J Pancreatol. 1991. PMID: 1744452
-
Release and binding of epidermal growth factor in the pancreas of rats.Int J Pancreatol. 1992 Feb;11(1):9-17. doi: 10.1007/BF02925987. Int J Pancreatol. 1992. PMID: 1583356
-
The enlargement of the hormone immune deprivation concept to the blocking of TGFalpha-autocrine loop: EGFR signaling inhibition.Cancer Immunol Immunother. 2006 Jun;55(6):628-38. doi: 10.1007/s00262-005-0030-9. Epub 2005 Nov 18. Cancer Immunol Immunother. 2006. PMID: 16328386 Free PMC article.
-
A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10217-21. doi: 10.1073/pnas.91.21.10217. Proc Natl Acad Sci U S A. 1994. PMID: 7937865 Free PMC article.
-
Comparative mitogenic potencies of EGF and TGF alpha and their dependence on receptor-limitation versus ligand-limitation.Med Biol Eng Comput. 1998 Jul;36(4):499-507. doi: 10.1007/BF02523222. Med Biol Eng Comput. 1998. PMID: 10198537
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials